source
- FDA advisory committee meetings sow confusion, threaten trust with rare disease developersThe Food and Drug Administration has been working to repair its relationship with rare-disease drug makers and patient groups since former commissioner Marty Makary left three months ago. Last wee…
- Gilead pushes into inflammation and oncology as it seeks to diversify beyond HIV franchiseGilead reported that HIV remained its strongest franchise in the second quarter, but the company is actively building a pipeline outside virology. CEO Daniel O’Day told investors that diversificat…